Assessing the Cardiac Risks of Cobalt in Hip Replacements

A technique for measuring the cardiac risk associated with cobalt – containing hip replacements has been highlighted for the first time in research at the University of Strathclyde.

Some hip replacements can contain Cobalt and could potentially affect heart function in some patients. The study has also identified, for the first time, a link between cobalt-induced changes in calcium levels in heart muscle cells and reduced contraction of the heart.

The Strathclyde study, funded by Heart Research UK, aimed to investigate the damaging effects of cobalt on heart cells and tissue. The research team examined a potential relationship between cobalt exposure and changes in the levels and activity of a protein called CaMKII. This protein is known to play a central role in regulating heart function in both health and disease.

The researchers looked at the best way to measure cobalt-induced effects in patients. Global longitudinal strain, a sensitive form of ultrasound, was found to be a good way of measuring which hip replacement patients are most at risk of heart complications. The researchers also measured the impact of cobalt across a range of experimental settings, including its effects on two types of heart cells and on cardiovascular function in both a laboratory model and humans.

The research demonstrated that cobalt, even at low levels, can reduce heart contraction, making the heart less efficient at pumping blood around the body. Calcium plays a key role in regulating heart contraction and it is thought that the effects of cobalt on CaMKII and calcium levels within the heart cells contributes to this reduction in contraction. The results from the study highlight the potential for both early intervention and prevention of damaging effects of cobalt in the heart.

The research team comprised scientists in Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) and the University’s Department of Biomedical Engineering, along with Orthopaedic clinicians at Queen Elizabeth University Hospital.

Dr Susan Currie, a Reader in SIPBS, is leading the research. She said: “Hip replacements are the current treatment for advanced cases of arthritis. However, there is now very strong evidence of a link between hip replacements where metals such as cobalt and chromium are used in the artificial joint bearings, and the possibility of developing heart complications.

“While not all hip replacements contain cobalt, for those that do, cobalt levels can rise over time in the bloodstream of patients and the metal can accumulate in various organs of the body, including the heart. Left untreated, this can damage the heart and, in some cases, lead to heart failure, but doctors cannot tell whether, or when, hip replacement patients will develop heart complications.

“Despite the knowledge that cobalt in some hip replacements has the potential to cause heart complications, our research is the first time a robust way of measuring risk has been found. This is also the first time that a link between cobalt-induced changes in calcium levels in heart muscle cells and reduced contraction of the heart has been identified. Cementing this knowledge will allow further study to focus on new treatments to reduce or prevent the toxic effects of cobalt in patients with hip replacements.

“Our findings confirm a mechanism by which cobalt can negatively impact heart function. This has significant implications in terms of care for people who have received hip replacements which contain cobalt and who therefore may be at increased risk for the development of longer-term cardiac complications.”

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.